Citations

Citations to this article as recorded by  

• Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease
  Kai Chen, Wei Shao, Huaxiong Zhang
  Medicine.2026; 105(4): e47098.     CrossRef
• Efficacy and Safety of Finerenone in Patients with Idiopathic Membranous Nephropathy: A Multicentre, Prospective-Retrospective Real-World Study
  Jia-Yi Li, Yu-Lin Zhu, Jian-Peng Zhang, Jia-Mei Lu, Xiao-Yong Yu, Jing E, Yang Wei, Dan-Na Ma, Akhmedova Nilufar Sharipovna, Jason Choo, Chieh Suai Tan, Min Qi, Yan Li, Xiao-tao Ma, Zhe Kang, Zhao Chen, Xiang-hui Chen, Rong-Guo Fu
  American Journal of Nephrology.2026; : 1.     CrossRef
• Finrenone and sodium-glucose cotransporter 2 inhibitor polypill: how “CONFIDENT” are we?
  Gerry George Mathew
  Kidney Research and Clinical Practice.2026; 45(2): 286.     CrossRef
• Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study
  Xu-Ying Liu, Ya-Min Zhao, Ya-Guang Zhang, Yi Liu, Bo-Ya Wang, Zhen-Zhen Hao, Man-Hui Hu
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
  Amy K. Mottl, Deirdre L. Sawinski, Petter Bjornstad
  American Journal of Kidney Diseases.2026; 87(5): 730.     CrossRef
• Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
  Amy K. Mottl, Kamlesh Khunti, Chantal Mathieu
  Diabetes, Obesity and Metabolism.2026; 28(5): 3568.     CrossRef
• Cardiovascular risk in primary aldosteronism: inflammatory drivers, residual risk, and emerging combination strategies
  Haoze Liu, Zejun Wu, Xinzhe Liu, Yuyuan Hu, Kaixuan Zhang, Jiwen Shang
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
  Qing Yang, Lijun Zhao, Jing Ma, Shuming Ji, Duolao Wang, Jing Li, Sheyu Li, Fang Liu
  Diabetes, Obesity and Metabolism.2026; 28(7): 6225.     CrossRef
• Finerenone: features of action, current evidence base and examples of clinical application
  A. D. Erlikh, E. V. Bublik, A. V. Zilov, O. S. Lebedeva, A. G. Farmanov, D. Y. Shchekochikhin
  Diabetes mellitus.2026; 29(2): 215.     CrossRef
• Finerenone exposure and ischaemic stroke in patients with type 2 diabetes and chronic kidney disease: A propensity score-matched cohort study
  Wu-Lung Chuang, Ruey-Hwang Chou, Yuan-Hung Wang, I-Ju Tsai, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang
  Clinical Medicine.2026; 26(5): 100617.     CrossRef
• Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort
  Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, Serpil Müge Değer, Mustafa Demir, Sümeyra Koyuncu, Üstün Yılmaz, Ayça İnci, Hülya Çolak, Bülent Demirel
  Clinical Kidney Journal.2026;[Epub]     CrossRef
• Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study
  Juan Pei, Xuejuan Sun, Xiuhua Xu, Peijin Bai, Ruihong Huang, Jun Zhang, Xing Chen, Lijing Yao, Leping Shao, Yinan Li
  Renal Failure.2026;[Epub]     CrossRef
• Omics Studies in CKD: Diagnostic Opportunities and Therapeutic Potential
  Merita Rroji, Goce Spasovski
  PROTEOMICS.2025;[Epub]     CrossRef
• Finerenona no Tratamento da Nefropatia Diabética: Perspectivas Atuais e Evidências Clínicas
  Rosana Maciel Schmidt, Luis Alberto Batista Peres, Alfredo Casagrande Laude
  Cuadernos de Educación y Desarrollo.2025; 17(3): e7760.     CrossRef
• Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
  Yu Sun, Mingzhu Wang
  International Urology and Nephrology.2025; 57(8): 2567.     CrossRef
• Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM
  Shadi Bazzazzadehgan, Zia Shariat-Madar, Fakhri Mahdi
  Biomolecules.2025; 15(3): 414.     CrossRef
• Renal function trajectories of Japanese adults with diabetic kidney disease on different diet therapies including energy-restricted and low-carbohydrate diets: a retrospective cohort study
  Tomomi Shirai, Sakiko Inaba, Miyu Maemura, Maki Saho, Miyu Sato, Mariko Sanada, Yoko Tsukamoto, Gaku Inoue, Taichi Nagahisa, Shinichi Tanaka, Hajime Tanaka, Hideaki Kurata, Takeshi Katsuki, Toshihide Kawai, Satoru Yamada
  Diabetology International.2025; 16(3): 493.     CrossRef
• Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy
  Lingli Ma, Dianyuan Liu, Yue Yu, Zimeng Li, Qing Wang
  Frontiers in Immunology.2025;[Epub]     CrossRef
• Finerenone’s safety and efficacy in membranous nephropathy: an emerging perspective
  Aqsa Afzal, Ayesha Fatima, Ayesha Abdul Razzaq
  International Urology and Nephrology.2025; 57(10): 3479.     CrossRef
• A Novel Therapy of Finerenone and Dapagliflozin for Lipoprotein Glomerulopathy
  Haowen Lin, Yuhe Yin, Jianchao Ma, Shuangxin Liu
  Kidney International Reports.2025; 10(10): 3696.     CrossRef
• Intensive glycemic control and kidney disease risk: insights on hierarchical composite endpoint from a randomized clinical trial
  Zhaojie Song, Haibao Xu, Jiaheng Zhang, Yezhou Liu, Chao Li, Tao Chen, Sujuan Guo, Ni Zhu
  Frontiers in Medicine.2025;[Epub]     CrossRef
• Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease
  Eleni Hughes, Xiaoxin X. Wang, Lily Sabol, Keely Barton, Sujit Hegde, Komuraiah Myakala, Ewa Krawczyk, Avi Rosenberg, Moshe Levi
  American Journal of Physiology-Renal Physiology.2025; 329(4): F510.     CrossRef
• Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies
  Yi Lv, Chen Ye, Zixi Li, Jiajia Ye, Huanhuan Cao, Chun Zhang, Huajun Jiang, Yumei Wang
  Diabetes/Metabolism Research and Reviews.2025;[Epub]     CrossRef
• Nephroprotective activity of naringenin in gentamicin-induced nephrotoxicity in male Wistar rats: In-vivo and in-silico evaluation
  William Bwambale, Victor Otu Oka, Ekom Monday Etukudo, Daniel Udofia Owu, Etah Etah Nkanu, Idara Asuquo Okon, Saali Dembe Emmanuel, Umar Uthman Shehu, Ntoni Wilber, Allan Kambere, Richard Arinaitwe, Venesio Bwambale
  Pharmacological Research - Natural Products.2025; 9: 100406.     CrossRef
• The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation
  Komuraiah Myakala, Xiaoxin X. Wang, Nataliia Shults, Eleni P. Hughes, Patricia de Carvalho Ribeiro, Rozhin Penjweini, Katie Link, Keely Barton, Ewa Krawczyk, Cheryl Clarkson Paredes, Anastas Popratiloff, Jay R. Knutson, Ashley L. Cowart, Moshe Levi
  American Journal of Physiology-Renal Physiology.2025; 329(5): F724.     CrossRef
• Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
  Xue-Dong An, Xin-Qin Li, He Zhang, Qian-You Jia, Yue-Hong Zhang, Gui-Gui Yang
  World Journal of Diabetes.2025;[Epub]     CrossRef
• Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System
  Markus van der Giet
  CardioVasc.2024; 24(1): 33.     CrossRef
• Chicoric acid advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway
  Weiwei Zhang, Yong Liu, Jiajun Zhou, Teng Qiu, Haitang Xie, Zhichen Pu
  Clinical and Experimental Hypertension.2024;[Epub]     CrossRef
• Endothelial CXCR2 deficiency attenuates renal inflammation and glycocalyx shedding through NF-κB signaling in diabetic kidney disease
  Siyuan Cui, Xin Chen, Jiayu Li, Wei Wang, Deqi Meng, Shenglong Zhu, Shiwei Shen
  Cell Communication and Signaling.2024;[Epub]     CrossRef
• Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
  Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi
  International Journal of Molecular Sciences.2024; 25(7): 3969.     CrossRef
• Rediscovery of the Implication of Albuminuria in Heart Failure: Emerging Classic Index for Cardiorenal Interaction
  Kyung-Duk Min, Yuki Matsumoto, Masanori Asakura, Masaharu Ishihara
  ESC Heart Failure.2024; 11(6): 3470.     CrossRef
• Decoding the role of aldosterone in glycation-induced diabetic complications
  Mayura Apte, Saee Zambre, Pratiksha Pisar, Bishnudeo Roy, Rashmi Tupe
  Biochemical and Biophysical Research Communications.2024; 721: 150107.     CrossRef
• Exploring the potential of finerenone in non-diabetic chronic kidney disease: a promising frontier
  Ayesha Maryam, Muhammad Salman Nadeem, Ayesha Fatima, Kashaf Noor Asmat
  International Urology and Nephrology.2024; 57(1): 295.     CrossRef
• A new perspective on proteinuria and drug therapy for diabetic kidney disease
  Ruimin Zhang, Qian Wang, Yaqing Li, Qihu Li, Xuefeng Zhou, Xiangmei Chen, Zheyi Dong
  Frontiers in Pharmacology.2024;[Epub]     CrossRef
• Molecular Therapeutics for Diabetic Kidney Disease: An Update
  Man Guo, Fangfang He, Chun Zhang
  International Journal of Molecular Sciences.2024; 25(18): 10051.     CrossRef
• Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats
  Tham Thi Bui, So-Hyeon Kim, Woojin Jung, Sung-yoon Yang, Quyen Thi Tran, Hyunjung Lee, Seongwon Park, Lien Thi Ngo, Hwi-yeol Yun, Jung-woo CHAE
  European Journal of Drug Metabolism and Pharmacokinetics.2024; 49(6): 701.     CrossRef
• A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
  Shuhui Zhai, Baisheng Ma, Weiwei Chen, Qini Zhao
  Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
• Exercise as a therapeutic approach to alleviate diabetic kidney disease: mechanisms, clinical evidence and potential exercise prescriptions
  Rao Fan, Jianda Kong, Jiahao Zhang, Lei Zhu
  Frontiers in Medicine.2024;[Epub]     CrossRef
• Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
  Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi
  Kidney and Blood Pressure Research.2024; 49(1): 1041.     CrossRef
• Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
  Akshyaya Pradhan, Umesh Chandra Tripathi
  The Egyptian Heart Journal.2024;[Epub]     CrossRef
• The Impact of Finerenone on Changes in Pulse Wave Velocity, Arterial Pressure and Heart Related Deaths in Hemodialysis Patients—Study Perspective
  Ljiljana Fodor Duric, Bozidar Vujicic, Tonko Gulin, Matko Gulin
  Open Journal of Nephrology.2024; 14(02): 216.     CrossRef
• Epigenetic modification in diabetic kidney disease
  Zhe Liu, Jiahui Liu, Wanning Wang, Xingna An, Ling Luo, Dehai Yu, Weixia Sun
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
  Sandra Martínez-Hernández, Martín Muñoz-Ortega, Manuel Ávila-Blanco, Mariana Medina-Pizaño, Javier Ventura-Juárez
  Biomedicines.2023; 11(10): 2828.     CrossRef
• Finerenone and other future therapeutic options for Alport syndrome
  Helen Pearce, Holly Mabillard
  Journal of Rare Diseases.2023;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Effectiveness and safety of chronic diuretic use in older adults: an umbrella review of recently published systematic reviews and meta-analyses of randomized-controlled trials
  Eveline van Poelgeest, Konstantinos Prokopidis, Tuğba Erdogan, Min Ji Kwak, Karolina Piotrowicz, Luca Paoletti, Annette Eidam, Fatma Özge Kayhan Koçak, Birkan Ilhan, Alessia Beccacece, George Soulis, Serdar Özkök, Gulistan Bahat, Eva Topinková, Joost Daam
  European Geriatric Medicine.2025; 16(4): 1353.     CrossRef
• Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
  Ji-Guang WANG
  Journal of Geriatric Cardiology.2025; 22(1): 1.     CrossRef
• Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome
  Tanawat Attachaipanich, Kotchakorn Kaewboot, Suthinee Attachaipanich
  Future Cardiology.2025; 21(11): 929.     CrossRef
• Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety
  Yonglu Hu, Chengqian Li, Shufa Li, Lili Xu, Yangang Wang, Bingzi Dong
  Diabetes/Metabolism Research and Reviews.2025;[Epub]     CrossRef
• OPTIMIZING ANTIHYPERTENSIVE THERAPY IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS: A REVIEW OF DOSE ADJUSTMENTS AND CLINICAL CONSIDERATIONS
  KANCHAN SHELKE, TEJAS PARKHE, DHANRAJ SHINDE
  International Journal of Pharmacy and Pharmaceutical Sciences.2025; : 25.     CrossRef
• Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors
  M. Sanz-Gómez, F.J. Manzano-Lista, E. Vega-Martín, D. González-Moreno, M. Alcalá, M. Gil-Ortega, B. Somoza, C. Pizzamiglio, L.M. Ruilope, I. Aránguez, P. Kolkhof, R. Kreutz, M.S. Fernández-Alfonso
  Biomedicine & Pharmacotherapy.2023; 168: 115661.     CrossRef
• Research Progress in Finerenone in Cardiovascular Diseases
  Sun Xue, Dong Yanghong, Gu Jiaxin, Liu Wenxiu, Liu Yue
  Cardiovascular Innovations and Applications.2023;[Epub]     CrossRef